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Featuring the questionable transparency of some COVID-19 data,
retraction notices and clinical trial results, what COVID-19 has taught
us about open access, a centralized archive of COVID-19 preprints,
and how the pandemic may affect the public’s trust in science.
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Data transparency amid COVID-19 journal retractions via the BMJ
The lessons learned from the British Medical Journal (BMJ)’s interrogation
of the questionable data transparency surrounding the use of oseltamivir
(Tamiflu) in 2009 do not seem to have been applied to clinical research on
COVID-19. Two recently retracted papers published in The Lancet and
The New England Journal of Medicine used a third-party data analytics
company (Surgisphere) that refused to comply with peer review requests
for access to datasets, leading their authors to request a retraction. Both
journals are signatories of the Wellcome Trust’s agreement on COVID-19
data sharing, but Dr Henry Drysdale (Clinical Researcher, Evidence-Based
Medicine DataLab, University of Oxford) suggests that the drive to produce
and disseminate COVID-19 research quickly could be compromising the
integrity and transparency of the associated data.
Transparency around retraction notices via Nature
In light of the notable retractions mentioned above, Dr Quan-Hoang Vuong
(Director, Centre for Interdisciplinary Social Research, Phenikaa
University) calls for retraction notices to be more consistent and
informative. His previous analysis of over 2000 retraction notices,
published in Learned Publishing, found that over half of the notices failed
to disclose the initiator of the retraction, and nearly 10% omitted the
reason for retraction.
30% of clinical trials are not transparent via TranspariMED
New data available on the Food and Drug Administration (FDA)
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Amendments Act Trials Tracker indicate that the results of approximately
30% of registered clinical trials are currently unreported on
ClinicalTrials.gov, leaving over $10 billion in uncollected FDA fines.
What COVID-19 has taught us about open access via cOAlition S
From the acceleration of preprint publication services to the lifting of press
embargoes and paywalls, the COVID-19 pandemic has transformed
scientific communication. Here, Professor Johan Rooryck (Professor of
French linguistics, Leiden University, and Open Access Champion,
cOAlition S) outlines how the global research community has responded to
demands for open access and how the transition towards open access has
been accelerated.
Collating COVID-19 preprints via Europe PMC
Most COVID-19 preprints are available as PDFs and are hosted across a
range of preprint servers without the level of standardized and consistent
access that enables machine learning and systematic searching. With the
support of the Swiss National Science Foundation, the UK Medical
Research Council and the Wellcome Trust, Europe PMC is collating and
hosting an archive of COVID-19 preprints from across the repertoire of
preprint servers, with the full texts available directly on its website to
enable accessible searching and data extraction.
Public trust in science after a pandemic via Times Higher Education
How does a pandemic affect the public’s perception of science and the
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Tweet
scientific community? A report in The London School of Economics’
Systemic Risk Centre discussion paper series found that the public’s level
of trust in individual scientists declined following historical epidemics, but
that the negative trend was not reflected in the public’s confidence in
science. One of the report’s authors, Dr Cevat Giray Aksoy (Assistant
Professor of Economics, King’s College London), suggests that failure to
communicate science in an accessible manner may be driving this trend.
We at Open Pharma would like to continue to encourage all our
readers to look after themselves and their community and continue to
follow advice from their country’s government and health
organizations.
Coronavirus mental health and wellbeing resources:
Mind UK
Mental Health Foundation UK
Centre for Disease Control and Prevention
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